The VA study was a hit piece.

I develop a lot of the chronic condition reporting for a company and that VA study was the worst.

1. They picked members that had multiple co-morbiddies, and like the serious ones. I remember seeing cancer patients on there
2. They gave the HCQ without the full stack in the z-pac, and they gave it to them way too late.
3. That report STILL SHOWED that the members that had it early enough were LESS likely to go to ventilators. And they had a higher discharge rate...but the amount of people that DIED during the study got the focus.
4. Also, and most importantly, there were multiple people on that report that had money/funding by the Gilead Sciences company. Those people made Remdesivir.

For anyone new to this ,Remdesivir is known for:

• Being $1000 a pill versus I think $6 a pill with HCQ. (I cant remember the numbers but I know I've seen reports that said the entire HCQ treatment package (6 days of pills) is like less than $100 in generic drugs
• Remdesivir/Gilead can be tied to ownership/stake by Faucci
• and Remmy had really poor phase 3 trials. Phase 3 trials are when they open up the test subjects to like 3k people instead of <100. (Not a pharmacist so please don't attack me if I am off by the numbers exactly). But this means that it worked at a good percentage when the pool was <100, but it wasn't spectacular results for larger groups.